STOCK TITAN

Boston Scientific (NYSE: BSX) director adds 4,450 company shares

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Boston Scientific Corp director David C. Habiger reported buying additional company stock in two recent open-market transactions. He purchased 2,200 shares of Common Stock on May 19, 2026 at a weighted average price of $56.9451 per share, and 2,250 shares on May 20, 2026 at a weighted average price of $55.9195 per share. According to the filing, individual trades on each day occurred within narrow price ranges around these averages. Following these purchases, Habiger directly owns 13,878 Boston Scientific common shares.

Positive

  • None.

Negative

  • None.
Insider Habiger David C
Role null
Bought 4,450 shs ($251K)
Type Security Shares Price Value
Purchase Common Stock 2,250 $55.9195 $126K
Purchase Common Stock 2,200 $56.9451 $125K
Holdings After Transaction: Common Stock — 13,878 shares (Direct, null)
Footnotes (1)
  1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.93 to $56.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $55.85 to $56.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Total shares bought 4,450 shares Open-market purchases on May 19–20, 2026
May 19 purchase 2,200 shares Common Stock, open-market on May 19, 2026
May 19 weighted avg price $56.9451 per share Trades ranged from $56.93 to $56.96
May 20 purchase 2,250 shares Common Stock, open-market on May 20, 2026
May 20 weighted avg price $55.9195 per share Trades ranged from $55.85 to $56.00
Shares owned after trades 13,878 shares Direct Common Stock holdings post-transactions
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average purchase price financial
"Represents the weighted average purchase price. These shares were purchased"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
U.S. Securities and Exchange Commission regulatory
"provide upon request by the U.S. Securities and Exchange Commission staff"
The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Habiger David C

(Last)(First)(Middle)
300 BOSTON SCIENTIFIC WAY

(Street)
MARLBOROUGH MASSACHUSETTS 01752-1234

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026P2,200A$56.9451(1)11,628D
Common Stock05/20/2026P2,250A$55.9195(2)13,878D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.93 to $56.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
2. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $55.85 to $56.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
/s/ Susan Thompson, Attorney-in-Fact05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Boston Scientific (BSX) disclose for David C. Habiger?

Boston Scientific disclosed that director David C. Habiger bought a total of 4,450 Common Stock shares in open-market transactions on May 19 and 20, 2026. These purchases increased his direct holdings to 13,878 shares, according to the Form 4 filing.

On what dates did David C. Habiger buy Boston Scientific (BSX) shares?

David C. Habiger purchased Boston Scientific Common Stock on May 19, 2026 and May 20, 2026. The Form 4 shows separate open-market purchases on each date, totaling 4,450 shares combined across both days, all held directly after the transactions.

How many Boston Scientific (BSX) shares does David C. Habiger own after these trades?

After the reported trades, David C. Habiger directly owns 13,878 Boston Scientific Common Stock shares. This figure reflects his position following two open-market purchases totaling 4,450 shares executed on May 19 and May 20, 2026, as detailed in the Form 4.

What prices did David C. Habiger pay for Boston Scientific (BSX) shares?

Habiger’s May 19, 2026 purchase had a weighted average price of $56.9451 per share, with trades between $56.93 and $56.96. His May 20, 2026 purchase had a weighted average price of $55.9195, with trades between $55.85 and $56.00.

Were David C. Habiger’s Boston Scientific (BSX) trades open-market purchases?

Yes. The filing classifies both transactions as open-market purchases of Common Stock under transaction code P. The shares were bought directly by David C. Habiger, rather than through derivatives or indirect entities, and are reported as non-derivative holdings.

Do the Boston Scientific (BSX) insider trades involve derivative securities?

No. The reported transactions involve only non-derivative Common Stock purchases. The derivative section of the Form 4 shows no option or other derivative transactions, and the derivativeSummary is empty, indicating no derivative exercises or conversions in this particular filing.